Q
Qifu Li
Researcher at Chongqing Medical University
Publications - 136
Citations - 3031
Qifu Li is an academic researcher from Chongqing Medical University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 21, co-authored 108 publications receiving 1905 citations. Previous affiliations of Qifu Li include University of Pittsburgh.
Papers
More filters
Journal ArticleDOI
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients With Diabetes and Albuminuria: A Systematic Review and Meta-Analysis
TL;DR: In patients with diabetes and albuminuria, ARBs reduced risks of ESRD and doubling of the serum creatinine level, and based on the renoprotective effects, ARB may be preferred for diabetic patients withalbuminuria.
Journal ArticleDOI
A Novel Visceral Adiposity Index for Prediction of Type 2 Diabetes and Pre-diabetes in Chinese adults: A 5-year prospective study
Jinshan Wu,Lilin Gong,Qifu Li,Jinbo Hu,Shuping Zhang,Yue Wang,Huang Zhou,Shuming Yang,Zhihong Wang +8 more
TL;DR: The data demonstrate that the CVAI is a better predictor of type 2 diabetes and pre-diabetes than the VAI, BMI, waist circumference, waist- to-hip ratio and waist-to-height ratio in Chinese adults.
Journal ArticleDOI
Roles of Chronic Low-Grade Inflammation in the Development of Ectopic Fat Deposition
TL;DR: In this review, the evidence linking inflammation with ectopic fat deposition is collected to get a better understanding of the underlying mechanism, which may provide a novel therapeutic strategies for metabolic disorders.
Journal ArticleDOI
Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis.
Peng Ye,Shumin Yang,Wenlong Zhang,Qiong Lv,Qingfeng Cheng,Mei Mei,Ting Luo,Lulu Liu,Shumei Chen,Qifu Li +9 more
TL;DR: The tolerability of febuxostat for the treatment of hyperuricemia with/without gout is similar to that of allopurinol, and febUXostat (40-120 mg/d) was more efficacious compared with allopURinol (100-300mg/d).
Journal ArticleDOI
Disruption of adenosine 2A receptor exacerbates NAFLD through increasing inflammatory responses and SREBP1c activity
Yuli Cai,Honggui Li,Mengyang Liu,Ya Pei,Juan Zheng,Juan Zheng,Jing Zhou,Xianjun Luo,Wenya Huang,Linqiang Ma,Linqiang Ma,Qiuhua Yang,Qiuhua Yang,Shaodong Guo,Xiaoqiu Xiao,Qifu Li,Tianshu Zeng,Fanyin Meng,Heather Francis,Shannon Glaser,Lulu Chen,Yuqing Huo,Yuqing Huo,Gianfranco Alpini,Chaodong Wu +24 more
TL;DR: It is demonstrated that disruption of A2AR in both macrophage and hepatocytes accounts for increased severity of NAFLD, likely through increasing inflammation and through elevating lipogenic events due to stimulation of SREBP1c expression and transcription activity.